Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01849874 · ClinicalTrials.gov registry record · Phase 3
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 341
- Enrollment target
NCT01849874 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 341 participants.
The verdict
NCT01849874, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 341 participants
- Enrollment target
Study Summary
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will receive either investigational study drug MEK162 or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan). Patients will be followed to compare the effectiveness of the study drug to that of the selected chemotherapies. Patients may be eligible to crossover from physician's choice chemotherapy to MEK162 if they meet certain inclusion criteria including centrally confirmed disease progression. Approximately 360 patients from North America, Europe and Australia will be enrolled in this study.
Interventions
- DRUG Physician's choice chemotherapy
- DRUG MEK162, MEK inhibitor; oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2013-06-27 |
| Est. Completion | 2022-08-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01849874
The ClinicalTrials.gov registry entry for NCT01849874 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Physician's choice chemotherapy is the first listed.
NCT01849874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01849874 about?
NCT01849874 is a clinical study titled "A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer". The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will receive either investigational study drug MEK162 or a chemotherapy chosen ...
What is the current status of trial NCT01849874?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 341 participants. The study started on 2013-06-27. Estimated completion is 2022-08-23.
What interventions are being tested in trial NCT01849874?
The interventions under investigation include: Physician's choice chemotherapy (DRUG), MEK162, MEK inhibitor; oral (DRUG).
Who is sponsoring clinical trial NCT01849874?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.